Goodwill Investor Education Eagle’s Eyes – AuroPharma shines !

Goodwill Investors’ Education:                                                 4th June 2020

Eagle’s Eyes:  Stock Market Today- A review:

Corona triggers Pharma Stocks:

Nifty Pharma Index today touched 10090 mark.

Aurobindo Pharma shines with robust Q 4 results.

Today Auropharma  is @ Rs. 756 after touching a High of Rs791

Aurobindo Pharma- known as Auropharma in bourses,  is primarily into producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product range  is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals anti-allergies and anti-diabetics drugs which are quite popular amongst the Doctors and patients.

Aurobindo Pharma was  up today by over 3 % to Rs 791 after consolidated net profit jumped 45.2% to Rs 849.80Cr on a 16.6% rise in net sales to Rs 6063.40 Cr in Q4 2020 vis a vis Q4 2019.

Consolidated PBT is at Rs 1077.51 Cr in Q4 2020, up by  32% from Rs 816.34 crore in Q4 2019. Total tax expenses were down by  1.12% to Rs 228.52 Cr in Q4 March 2020 against Q4 2019. The company reported deferred tax reversal of Rs 101.03 Cr in Q4 M 2020 against Q4 2019. The company has gained through deferred tax reversal of Rs 101.03 crore in Q4.

Consolidated EBITDA was up by  26.6% to Rs 1342 in Q4  2020 from Rs 1060 crore in Q4  2019. EBITDA margin improved to 21.8% in Q4  2020 from 20% in Q4 2019. The company has invested substantial amount in Research & Development to the tune of  Rs 239 crore, 3.9% of revenue.

US formulation sales stood at Rs 2,990.3 crore in Q4, a growth of 20.5% from Rs 2,481.1 crore in Q4 2019. Europe formulation sales stood at Rs 1,652.5 crore, an increase of 26% from the same period last year. API sales for the quarter declined 17.6% and stood at Rs 755.6 cr in Q4 2020 as against Rs 916.8 crore in Q4 2019. The pharmaceutical company reduced its net debt to Rs 2718.4 crore in 2020 from Rs 3181.9 crore in December 2019 and Rs 5008.1 crore in March 2019.

Commenting on the company’s performance, N. Govindarajan,M.D of the company said: “The new fiscal year has begun with lot of challenges that the globe and industry had never witnessed. We are committed in protecting the health and wellbeing of our employees, their families and other stakeholders. We have closed FY20 with a healthy performance in Q4. The growth was seen across all our geographies. Diversified product basket has helped us to maintain the growth momentum in our core geographies like USA and Europe. We remain focused on strengthening our existing businesses, developing a differentiated  and specialty product basket and regulatory compliance.” On a consolidated basis, net profit rose 20% to Rs 2829.51 crore on 18.3% rise in net sales to Rs 22737.95 crore in fiscal year 2020 over fiscal year 2019.

Leave a reply:

Your email address will not be published.

Site Footer